Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Kythera Biopharmaceuticals

Criteria

Inclusion Criteria:

• Healthy males or nonpregnant females

• Age 18 to 65

• Sufficient submental fat for injections

• Signed informed consent

Exclusion Criteria:

• Prior interventions in the chin or neck area

• History or presence of drug or alcohol abuse

• Treatment with an investigational agent within 30 days before the dose